PDF(Pubmed)
Abstract：
UNASSIGNED: To understand the characteristics of the intestinal microbiota after oral tolerance in infants with food protein-induced proctocolitis (FPIAP) treated with amino acid formula and their differences from healthy children, aiming to provide a scientific basis for guiding the application of probiotics during treatment.
UNASSIGNED: FPIAP infants were prospectively enrolled, fecal specimens were obtained, and DNA was extracted for PCR amplification of the bacterial 16S rRNA gene V4 region. Library construction and sequencing were performed, and bioinformatic analysis was performed after obtaining valid data.
UNASSIGNED: There were 36 patients in the FPIAP group: 20 males and 16 females, age 21.944 ± 13.277 months. Diarrhea with blood in the stool were the main symptom, with an average course of 14.83 ± 9.33 days. Thirty infants (83.33%) had mucus stool, 11.11% (4/36) of them experiencing vomiting, and 55.56% (20/36) of the infants displaying poor intake and weight gain, 28 (77.78%) patients with moderate eczema, 2 (5.6%) patients with chronic respiratory symptoms. The treatment time with amino acid formula was 5.51 ± 2.88 months. A control group comprising of 25 healthy infants who were full-term, natural delivery, bottle fed, and matched in terms of age (24.840 ± 12.680 months) and gender (15 males and 10 females) was selected. Anaerobic bacteria were less abundant in FPIAP infants than healthy infants (P = 4.811 × 10-5), but potentially pathogenic bacteria were more abundant (P = 0.000). The abundance of Actinobacteria was low in FPIAP infants, the abundance of Proteobacteria was high, and the abundance of Firmicutes was reduced. Bifidobacterium could be used as a bacterial genus to differentiate healthy and FPIAP infants. Both α-and β-diversity indicators of intestinal microbiota were lower in FPIAP infants. In FPIAP infants, glucose and energy metabolism and amino acid anabolism were decreased, and inflammation-related lipopolysaccharide synthesis pathways were increased.
UNASSIGNED: Compared with healthy infants, FPIAP infants with oral tolerance after amino acid formula treatment had differences in the structure and diversity of intestinal microbiota, among which Bifidobacterium was significantly reduced.
UNASSIGNED: This trial was registered on https://register.clinicaltrials.gov/.
UNASSIGNED: FPIAP infants were prospectively enrolled, fecal specimens were obtained, and DNA was extracted for PCR amplification of the bacterial 16S rRNA gene V4 region. Library construction and sequencing were performed, and bioinformatic analysis was performed after obtaining valid data.
UNASSIGNED: There were 36 patients in the FPIAP group: 20 males and 16 females, age 21.944 ± 13.277 months. Diarrhea with blood in the stool were the main symptom, with an average course of 14.83 ± 9.33 days. Thirty infants (83.33%) had mucus stool, 11.11% (4/36) of them experiencing vomiting, and 55.56% (20/36) of the infants displaying poor intake and weight gain, 28 (77.78%) patients with moderate eczema, 2 (5.6%) patients with chronic respiratory symptoms. The treatment time with amino acid formula was 5.51 ± 2.88 months. A control group comprising of 25 healthy infants who were full-term, natural delivery, bottle fed, and matched in terms of age (24.840 ± 12.680 months) and gender (15 males and 10 females) was selected. Anaerobic bacteria were less abundant in FPIAP infants than healthy infants (P = 4.811 × 10-5), but potentially pathogenic bacteria were more abundant (P = 0.000). The abundance of Actinobacteria was low in FPIAP infants, the abundance of Proteobacteria was high, and the abundance of Firmicutes was reduced. Bifidobacterium could be used as a bacterial genus to differentiate healthy and FPIAP infants. Both α-and β-diversity indicators of intestinal microbiota were lower in FPIAP infants. In FPIAP infants, glucose and energy metabolism and amino acid anabolism were decreased, and inflammation-related lipopolysaccharide synthesis pathways were increased.
UNASSIGNED: Compared with healthy infants, FPIAP infants with oral tolerance after amino acid formula treatment had differences in the structure and diversity of intestinal microbiota, among which Bifidobacterium was significantly reduced.
UNASSIGNED: This trial was registered on https://register.clinicaltrials.gov/.
摘要：
■了解用氨基酸配方治疗的食物蛋白诱导的直肠结肠炎（FPIAP）婴儿口服耐受后肠道菌群的特征及其与健康儿童的差异，旨在为指导益生菌在治疗过程中的应用提供科学依据。
■FPIAP婴儿前瞻性登记，获得粪便标本，提取DNA用于细菌16SrRNA基因V4区的PCR扩增。进行文库构建和测序，获得有效数据后进行生物信息学分析。
■FPIAP组36例，男20例，女16例，年龄21.944±13.277个月。腹泻伴便血是主要症状，平均病程为14.83±9.33天。30名婴儿(83.33%)有粘液便,其中11.11%(4/36)出现呕吐,55.56%(20/36)的婴儿表现出不良的摄入量和体重增加，28例（77.78%）中度湿疹患者，2例(5.6%)患者伴慢性呼吸道症状。氨基酸配方治疗时间为5.51±2.88个月。对照组由25名足月健康婴儿组成，自然交货,奶瓶喂养,选择年龄（24.840±12.680个月）和性别（男15例，女10例）相匹配。FPIAP婴儿的厌氧菌含量低于健康婴儿（P=4.811×10-5），但潜在致病菌较为丰富(P=0.000)。FPIAP婴儿的放线菌丰度较低，变形杆菌的丰度很高，Firmicutes的丰度减少了。双歧杆菌可用作细菌属以区分健康婴儿和FPIAP婴儿。FPIAP婴儿肠道菌群的α和β多样性指标均较低。在FPIAP婴儿中，葡萄糖和能量代谢和氨基酸合成代谢减少，炎症相关的脂多糖合成途径增加。
■与健康婴儿相比，经氨基酸配方治疗后口服耐受的FPIAP婴幼儿肠道菌群结构和多样性存在差异,其中双歧杆菌显著减少。
■此试验已在https://register上注册。临床试验.gov/.
■FPIAP婴儿前瞻性登记，获得粪便标本，提取DNA用于细菌16SrRNA基因V4区的PCR扩增。进行文库构建和测序，获得有效数据后进行生物信息学分析。
■FPIAP组36例，男20例，女16例，年龄21.944±13.277个月。腹泻伴便血是主要症状，平均病程为14.83±9.33天。30名婴儿(83.33%)有粘液便,其中11.11%(4/36)出现呕吐,55.56%(20/36)的婴儿表现出不良的摄入量和体重增加，28例（77.78%）中度湿疹患者，2例(5.6%)患者伴慢性呼吸道症状。氨基酸配方治疗时间为5.51±2.88个月。对照组由25名足月健康婴儿组成，自然交货,奶瓶喂养,选择年龄（24.840±12.680个月）和性别（男15例，女10例）相匹配。FPIAP婴儿的厌氧菌含量低于健康婴儿（P=4.811×10-5），但潜在致病菌较为丰富(P=0.000)。FPIAP婴儿的放线菌丰度较低，变形杆菌的丰度很高，Firmicutes的丰度减少了。双歧杆菌可用作细菌属以区分健康婴儿和FPIAP婴儿。FPIAP婴儿肠道菌群的α和β多样性指标均较低。在FPIAP婴儿中，葡萄糖和能量代谢和氨基酸合成代谢减少，炎症相关的脂多糖合成途径增加。
■与健康婴儿相比，经氨基酸配方治疗后口服耐受的FPIAP婴幼儿肠道菌群结构和多样性存在差异,其中双歧杆菌显著减少。
■此试验已在https://register上注册。临床试验.gov/.
